<i>IDH</i> Mutations in Glioma: Double-Edged Sword in Clinical Applications?
Discovery of point mutations in the genes encoding isocitrate dehydrogenases (IDH) in gliomas about a decade ago has challenged our view of the role of metabolism in tumor progression and provided a new stratification strategy for malignant gliomas. IDH enzymes catalyze the conversion of isocitrate...
Main Authors: | Alisan Kayabolen, Ebru Yilmaz, Tugba Bagci-Onder |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/7/799 |
Similar Items
-
Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma
by: Kang H, et al.
Published: (2020-10-01) -
Hypoxia and Microvascular Alterations Are Early Predictors of IDH-Mutated Anaplastic Glioma Recurrence
by: Andreas Stadlbauer, et al.
Published: (2021-04-01) -
A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database
by: Amrit L. Pappula, et al.
Published: (2021-08-01) -
Association of <i>TP53</i> Alteration with Tissue Specificity and Patient Outcome of <i>IDH1</i>-Mutant Glioma
by: Balazs Murnyak, et al.
Published: (2021-08-01) -
Promoter methylation analysis of IDH genes in human gliomas
by: Simon eFlanagan, et al.
Published: (2012-12-01)